BlackRock Inc. purchased a new stake in Encompass Health Corporation (NYSE:EHC - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,484,385 shares of the company's stock, valued at approximately $1,059,762,000. BlackRock Inc. owned 10.57% of Encompass Health at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WPG Advisers LLC grew its position in shares of Encompass Health by 73.3% during the 4th quarter. WPG Advisers LLC now owns 324 shares of the company's stock worth $34,000 after purchasing an additional 137 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in Encompass Health during the second quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd increased its stake in Encompass Health by 36,200.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company's stock worth $46,000 after acquiring an additional 362 shares during the period. Assetmark Inc. raised its holdings in Encompass Health by 89.6% in the 1st quarter. Assetmark Inc. now owns 455 shares of the company's stock valued at $44,000 after acquiring an additional 215 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Encompass Health during the 4th quarter valued at $55,000. 97.25% of the stock is owned by institutional investors and hedge funds.
Encompass Health Stock Down 0.6%
NYSE:EHC opened at $120.24 on Friday. Encompass Health Corporation has a one year low of $92.77 and a one year high of $127.99. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market cap of $11.86 billion, a PE ratio of 19.58, a P/E/G ratio of 2.45 and a beta of 0.72. The firm's 50 day simple moving average is $111.01 and its 200 day simple moving average is $106.38.
Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, topping analysts' consensus estimates of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business earned $1.40 earnings per share. Encompass Health's revenue was up 9.6% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. On average, research analysts anticipate that Encompass Health Corporation will post 6.08 earnings per share for the current year.
Encompass Health Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a $0.21 dividend. The ex-dividend date is Thursday, October 1st. This is a boost from Encompass Health's previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 0.7%. Encompass Health's dividend payout ratio (DPR) is currently 12.38%.
Insider Activity at Encompass Health
In other news, CEO Mark J. Tarr sold 173,148 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $125.47, for a total value of $21,724,879.56. Following the transaction, the chief executive officer owned 267,814 shares in the company, valued at approximately $33,602,622.58. The trade was a 39.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Patrick Darby sold 8,906 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the completion of the sale, the executive vice president directly owned 75,041 shares in the company, valued at approximately $9,451,413.95. This represents a 10.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.80% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently commented on EHC shares. Truist Financial raised their price target on Encompass Health from $140.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Encompass Health from a "hold" rating to a "buy" rating in a research report on Sunday, August 16th. Barclays increased their price objective on shares of Encompass Health from $140.00 to $144.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Encompass Health from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Finally, Leerink Partners set a $152.00 price target on shares of Encompass Health in a report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $148.71.
View Our Latest Stock Analysis on Encompass Health
About Encompass Health
(
Free Report)
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
